Clinical Trial

Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia

Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with chronic myelomonocytic leukemia (CMML) who have an intermediate-2 or high-risk prognosis. The main goal is to evaluate 1 year RFS and OS. Other goals include assessing engraftment, overall survival, transplant-related complications, and side effects. A total of 31 participants will be enrolled.
Protocol Amendment History 2 changes
critical Phase changed: Phase 4 -> not applicable 2026-05-27
notable Sponsor changed: Sun Yuqian -> Peking University People's Hospital 2026-05-27
Trial Details
NCT Number NCT07588594
Lead Sponsor Peking University People's Hospital
Conditions Chronic Myelomonocytic Leukemia (CMML)
Enrollment 31 participants
Start Date 2026-02-13
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-26